Several experts from different European countries agree that Electromagnetic Hypersensitivity is a real, physical illness and for some of them this condition seems to be strictly related to Multiple Chemical Sensitivity (MCS). This is what came out of the congress “Mobile Telephony, Wi-Fi, Wi-Max: Are there Health Risks?”, held at Palazzo Marini – Chamber of Deputees in Rome on 14 June 2011. The event, organized by the Association for Environmental and Chronic Toxic Injury (A.M.I.C.A.), was meant to give an overview on the health dangers linked to the use of wireless devices.

Prof. Dominique Belpomme, Oncologist, Professor of the Centre Hospitalier Universitaire Necker-Enfants Malades, Chairman of Research for Anti-Cancer Therapeutics (ARTAC), in his lecture “Diagnostic and Therapeutic Protocols for Electromagnetic Fields Intolerance”, showed the results of a clinical observation on more than 450 patients enrolled from 2008 to 2011. He and his team use a new technique to make the diagnosis to people reporting reactions to electromagnetic fields, a condition that he prefers to define as “Electromagnetic Fields Intolerance” or “EFI Syndrome” rather than “Electromagnetic Hyper-Sensitivity”.

The new technique is the “Pulsed Eco-Doppler” of the brain that combines the eco-doppler with a computer to evaluate brain perfusion. Unlike some other methods, this one is not dangerous and it does not involve any ionizing radiation. The results show that people with Electromagnetic Fields Intolerance have a reduced perfusion in the brain, particularly in the left part of the limbic area of the brain, compared to the control group. This is a very particular area, because it is the “ancient” part of the brain that controls many body functions.

“These results are very important – Belpomme said at the congress – because for the first time we are able to define the Electromagnetic Fields Intolerance as a physical illness based on objective tests”.

His team uses also other tests, such as the dosage of histamine, of protein S100B, and of heat shock proteins hsp70 and hsp27 in the blood. The 70% of the group of patients observed showed a serious reduction of vitamin D, about 1-2% of the patients showed an increase of proteins hsp27 and hsp70, while more than the 40% of the sample had increased histamine, a fact that is fully compatible with a physiological interpretation of this syndrome.

About 10% of the patients had an increased protein S100B, which is a marker for Blood Brain Barrier (BBB) permeability. In one third of the sample, a reduction of melatonin in urine was found, and this can explain symptoms such as fatigue, insomnia and depression in these patients.

These alterations are quite similar to the ones found in patients with Multiple Chemical Sensitivity (MCS), particularly regarding the brain perfusion reduction, the neurogenic inflammation, the oxidative stress increase, and the reduction of the defense mechanism. The fact that EMF induces the opening of the BBB may interfere with the brain protection from toxic chemicals. It is not uncommon, in fact, that patients with EFI Syndrome have MCS symptoms, while many patients with MCS also react to EMF.

The increase of oxidative stress in electrosensitive patients was found also by Dr. Valeria Pacifico, who lectured in Rome about “Metabolic biomarkers of oxidation-reduction imbalance and susceptibility to non-ionizing radiation”. She works in the team of Dr. Chiara De Luca at the Experimental Laboratory BILARA at Istituto Dermopatico of Immaculata in Rome that published several works on the role of oxidative stress in environmental sensitivities. (1, 2)

“To make a diagnosis of this syndrome we need to listen first to patients and we need to verify if the symptoms improve or disappear when they stay away from EMF sources”, Prof. Belpomme explained. In order to demonstrate if the electromagnetic fields were the real cause of the alterations found in these patients, the patients had to repeat the tests before and after a period of avoidance of EMF for three months. The results show that after the period of avoidance the levels tend toward the normal standard.

Given the strong correlation found by six epidemiologic studies on EMF exposure and Alzheimer Disease (AD), Prof. Belpomme believes that any electrosensitive patient with memory dysfunctions should be evaluated also for AD. He stresses the fact that AD is a loss of long term memory while EFI Syndrome often involves the loss of short term memory, but this symptom may be considered as a pre-Alzheimer condition.

Prof. Olle Johansson, Assoc. Prof., The Experimental Dermatology Unit, Department of Neuroscience, Karolinska Institute; Professor, The Royal Institute of Technology, Stockholm, talked in Rome about “The precautionary principle: from Bioinititive to the Seletun consensus”. He dedicated his lecture to people affected by EHS and MCS because “they have a very difficult life”.

He is one of the most dedicated scientists in the promotion of new biologically-based safety guidelines for EMF. He was in Benevento for the ICEMS resolution in 2006, then in London in 2007 for a new resolution, and he was also member of the group of independent scientists that published the famous Bioinitiative Report in 2007, which had strong ecological concern in the political agenda. Thanks to this report, in fact, the European Parliament signed a resolution on September 4, 2008 to state that the actual safety limits for EMF are obsolete and to warn EU governments about the increase of new environmental illnesses such as EHS, MCS and Dental Amalgam Mercury Syndrome.

More recently, Prof. Johansson was part of the group of scientists who prepared the Seletun Consensus, published last February in Reviews on Environmental Health (3). It states that present standards do not protect global human population from electromagnetic fields and all EMF should be reduced now instead of waiting for a definitive proof of danger. It also states that people reporting EHS symptoms should be considered as having a functional disability.

In Sweden, for example, EHS, MCS and fibromyalgia are already classified as functional disabilities. This means that people affected by these conditions are not considered patients, but it’s the environment that creates limitations for them so it’s the environment that has to be changed. This kind of classification represents the full concretization of the UN Convention on the Rights of Persons with Disabilities, signed by governments on March 30, 2007. This convention should be enough to push all governments to find the right accommodation and the best welfare strategies for people with environmental sensitivities, and put an end to discrimination.

Author: Francesca Romana Orlando, journalist and Vice President of A.M.I.C.A.

Literature:

1. De Luca C. et al., Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobiotic-metabolizing enzymes, Toxicology and Applied Pharmacology, YTAAP-11818; No. of pages: 8; 4C.
2. De Luca C. et al., The Search for Reliable Biomarkers of Disease in Multiple Chemical Sensitivity and Other Environmental Intolerances, Int. J. Environ. Res. Public Health 2011, 8, 2770-2797; doi:10.3390/ijerph8072770
3. Fragopoulou A ed al., Scientific panel on electromagnetic field health risks: consensus points, recommendations, and rationales, Rev Environ Health. 2010 Oct-Dec; 25(4):307-17.

Related Articles:

• WHO receives delegation of representatives for the environmentally ill
• An Italian Law Proposal for Environmental Illnesses and Disability
• International Conference: Environmental and chemical pollution cause health injuries and disabilities
• Italian Parties united under the MCS cause

Whilst facing a worldwide fast increase of food and environmental allergies, the medical community is also confronted with another inhomogeneous group of environment-associated disabling conditions, including multiple chemical sensitivity (MCS), fibromyalgia, chronic fatigue syndrome, electric hypersensitivity, amalgam disease and others. These share the features of poly-symptomatic multi-organ cutaneous and systemic manifestations, with postulated inherited/acquired impaired metabolism of chemical/physical/nutritional xenobiotics, triggering adverse reactions at exposure levels far below toxicologically-relevant values, often in the absence of clear-cut allergologic and/or immunologic involvement.

Due to the lack of proven pathogenic mechanisms generating measurable disease biomarkers, these environmental hypersensitivities are generally ignored by sanitary and social systems, as psychogenic or “medically unexplained symptoms”. The uncontrolled application of diagnostic and treatment protocols not corresponding to acceptable levels of validation, safety, and clinical efficacy, to a steadily increasing number of patients demanding assistance, occurs in many countries in the absence of evidence-based guidelines.

De Luca et. al. revised available information supporting the organic nature of these clinical conditions. Following intense research on gene polymorphisms of phase I/II detoxification enzyme genes, so far statistically inconclusive, epigenetic and metabolic factors are under investigation, in particular free radical/antioxidant homeostasis disturbances. The finding of relevant alterations of catalase, glutathione-transferase and peroxidase detoxifying activities significantly correlating with clinical manifestations of MCS, has recently registered some progress towards the identification of reliable biomarkers of disease onset, progression, and treatment outcomes.

Literature:

De Luca C, Raskovic D, Pacifico V, Thai JC, Korkina L., The search for reliable biomarkers of disease in multiple chemical sensitivity and other environmental intolerances, Tissue Engineering & Skin Pathophysiology Laboratory and 2nd Dermatology Division, Dermatological Research Institute (IDI IRCCS), Via Monti di Creta 104, Rome 00167, Italy; Int J Environ Res Public Health. 2011 Jul;8(7):2770-97. Epub 2011 Jul 1.

Related articles:

• Environmental Illnesses: Petition received the support from 26 countries more than 200 Health experts and more than 240 NGOs
• Research on Multiple Chemical Sensitivity (MCS)
• Study could not confirm link between mental illness and chemical sensitivity
• Predictions of Multiple Chemical Sensitivity Mechanism Confirmed by Roman Study

For those living with Environmental sensitivities, life is very difficult

In Quebec there are 170,000 people who have a medical diagnosis of Environmental Sensitivities Yet for most, their illness goes without proper medical treatments due to the lack of Government and Public Awareness, limited Doctor Training, and the need for a Designated Treatment Centre.

The Environmental Health Association of Québec (ASEQ-EHAQ) is a non-profit, charitable organization founded in 2004. Presently, membership of the group is over 1200. ASEQ-EHAQ’s mission encompasses not only support for people suffering from environmental sensitivities but also provides the community with resources to cope with the disease (education, help line, the latest information about environmental sensitivities and treatment, support meetings, healthy housing, a resource guide, newsletters…) ASEQ-EHAQ also works tirelessly to educate the community at large on the use of ecological strategies to maintain a healthy environment.

Environmental sensitivities is a chronic, disabling condition that is not always visually recognizable. It affects people of all ages – youth and children included. Many symptoms can be identified using published diagnostic guidelines.

Environmental sensitivities sufferers experience physical symptoms such as headaches and fatigue, when exposed to a wide range of chemical substances. Recent research is showing that there is a biological basis for the symptoms noted above. At this time, there is no known cure.

For those living with Environmental sensitivities, life is very difficult especially because awareness in the medical community is extremely limited. The few doctors who are knowledgeable about and treat Environmental sensitivities are stretched beyond capacity. Many patients are dismissed by their family doctors when a diagnosis is made. Others find it impossible to find a physician with the training to care for them. There are no education, treating or research centers in Quebec.

There is an urgent need for information to be made available to the public. People must have a greater understanding about the illness and the challenges faced by those who live with it. Help is also needed at the most basic levels of home and long-term care. Many people with this illness cannot care for themselves or their families. They cannot work and must rely on government support.

See the chart for a breakdown of the affected population in QUEBEC. These numbers exceed that of many other better-known chronic conditions.

It is costing the government both in direct health care costs and economic losses (as sufferers are forced to stop working). It is estimated the combined loss of productivity due to this illness in CANADA (affecting well over a million people) is more than 20 billion dollars annually, the direct medical cost itself over 2 billion dollars. The Quebec figures are proportionately staggering. The provincial government has an important role to play in improving the situation.

ASEQ-EHAQ strives to raise awareness within communities, corporations, governments, educational institutions, the medical community and the general public to prevent further cases of Environmental sensitivities. We will continue to work with all doctors, scientists, health and environmental groups and individuals across Canada to create ties with similar organizations throughout North America and overseas.

Environmental Health Association of Quebec

Contact: Michel Gaudet

Tel: 514.683.5701

office @ aseq-ehaq.ca

www.aseq-ehaq.ca

Related Articles:

• Environmental Illnesses: Petition received the support from 26 countries more than 200 Health experts and more than 240 NGOs
• MCS – Multiple Chemical Sensitivity: A Report from Denmark
• Spain: A cry for help, young woman in Danger
• An Italian law Proposal for Environmental Illnesses and Disability
• MCS in Japan: A Lecture at the House of Representatives of Japan

Today, May 12th, I have woken up locked up in the same place and I can still see that:

Society continues to poison me with its toxics, this cruel, unjust society that is so comfortable in its greediness, while it rejects me for not producing and not consuming as healthy bodies do, while the owners of the toxic industries laugh at me and get richer.

They abandon me and say that it is my fault that I live with this illness, as though it was a whim, as though I did not want to make an effort, as though it was something I made up to avoid going to work.

My body, my bed and my walls have become a prison with only my window and my thoughts as company, with no chance of parole in sight.

I am condemned to live in the shadows because I am what society wants to hide. I am part of the narrative that will never make it into the history books.

After years of working hard and paying taxes, I have no rights and I am excluded from the Welfare State. They consider me useless although what I really am is disabled.

My exile is imposed on me by administrations, politicians and doctors, the same ones who promised me they would be there to help me. They have betrayed me when I most needed them. Now they pretend I don’t exist. They act as though I was a bother and they make fun of me while they hide the fact that everyday there are more and more of us.

Although I can barely move, I have decided, once more, to be determined and brave. Visible despite being housebound. Weak and vulnerable but never a coward.

I have decided I will continue to live, to fight, despite my vulnerability. I will not be silenced although they want to shut me up.

This is what I have decided again this year. Once again, because nothing has changed.

I hope that you will do the same. Yes, you who are vulnerable, although you do not realize it. We need to continue to fight without giving up, to shake society’s comfortable thoughts and question how we live as a society. To question this “development” which is killing us slowly. Until those of us who are vulnerable are not defenseless anymore. Until there is justice, respect and tenderness for all.

Authors: No Fun and Liga SFC (CFS/ME League), Spain, May 12, 2011

* May 12th, International Day of Central Sensitivity Syndromes (Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis, Fibromyalgia and Multiple Chemical Sensitivity)

Related Articles:

• Environmental Illnesses: Petition received the support from 26 countries more than 200 Health experts and more than 240 NGOs
• No more discrimination for the ill
• WHO receives delegation of representatives for the environmentally ill
• MANIFESTO – We know they are lying to us

MCS stakeholders sign petition to the World Health Organization

On May 13, a petition from the WHO delegation of stakeholders from MCS and EMS patients, physicians, scientists, lawyers and journalists in Geneva will be received. The delegation will be welcomed by Dr. Maria Neira, Director General of Public Health and Environment, WHO confirms.

WHO confirmed hearing from MCS organizations

Dr. Neira will receive the relevant documents from the delegation, a bibliography regarding environmental diseases, a list of countries that already have a ICD-10 code for MCS and / or EMS, and some other relevant documents for the meeting. All documents being submitted support the science-based arguments, and finally create a mandatory basis for environmental health conditions worldwide, so that the medical care of patients can be assured.

MCS and EMS organizations sign the WHO petition

The petition, which seeks to ensure that the situation for people, who are chemically sensitive or electro-sensitive, was improved by the Spanish organization „Asquifyde”. The petition was signed by many organizations, researchers, and practitioners from around the world. The hope is that WHO will implement this petition, which would apply a consistent international code of disease (ICD) in all countries worldwide for those with Multiple Chemical Sensitivity (MCS) and electromagnetic sensitivity (EMS). This ICD code is important because it will allow patients’ doctors to give an accurate diagnosis with expected benefits from the health insurance, which already exists for other disabilities and illnesses. The existence of MCS and EMS has already been demonstrated.

In all countries, binding ICD-10 code for MCS and EMS

Currently, Japan (T65.9) and Germany (T78.4) have the ICD-10 code for MCS. Other German-speaking countries like Switzerland, Luxembourg and Austria ,through their Ministry of Health, say that in their countries the ICD-10 code for MCS, T78.4, is valid and can be used as well.

Submission of evidence to the WHO

It is possible to contribute and submit other important documents regarding the scientific aspects of MCS and EMS, to the WHO. During the next few days a PDF may be sent via e-mail to: info@asquifyde.es which is the Spanish organization. All documents received by medical experts and lawyers for environmental law will be organized in terms of their relevance and then selected for submission to the WHO.

Confirmed participation in the WHO hearing

Until May 3rd, 2011 it possible for organizations, academics, lawyers, and doctors to register for consultation with WHO in Geneva. This requires a binding confirmation take place with Asquifyde. The organization will report the final number of participants on May 3rd to Dr. Neira, after which it is appropriate to reserve a space.

WHO press conference after hearing

According to the WHO, a press conference will take place after the hearing. It will be headed by Sonia Miguel Jara and journalists. To fund this important press conference following the WHO hearing, Asquifyde and other MCS and EMS organizations, are asking anyone who is concerned about the environmental concerns of those ill from environmental factors to contribute financial support.

Help the environmentally ill

Scientists estimate that about 15-30% of the general population in industrialized countries suffer with MCS. The number of EMS stakeholders increases by the progressive expansion of mobile networks also. These people are almost without exception, without the help and support, which contradicts the international disability convention and applicable laws. Ignoring and negation of environmental diseases in recent years has led to indescribable suffering and to considerable financial losses to the economy. It is hoped that the leaders at the WHO, will respect the suffering of those patients with MCS and EMS and take seriously the international petition and act according to their stated mission which is to provide assistance to those disabled internationally.

Author: Silvia K. Müller, CSN – Chemical Sensitivity Network, 2 May 2011

Translation: Christi Howarth for CSN

Related articles:

• No more discrimination for the ill
• International Conference: Environmental and chemical pollution cause health injuries and disabilities
• ALERT: Spanish Professor with chronic mercury intoxication goes on hunger strike
• The last few months of Angelika S. who was chemically sensitive
• An Italian Multiple Chemical Sensitivity Sufferer Shouts an “Inconvenient” Truth with his Death

“Previous research suggests that the most successful treatment for fibromyalgia involves a combination of medications, physical exercise and development of coping skills,” said James Carson, Ph.D., a clinical health psychologist and an assistant professor of anesthesiology and perioperative medicine in the OHSU School of Medicine. “Here, we specifically focused on yoga to determine whether it should be considered as a prescribed treatment and the extent to which it can be successful.”

In this study, researchers enrolled 53 female study subjects previously diagnosed with fibromyalgia. The women were randomly assigned to two research groups. The first group participated in an eight-week yoga program, which included gentle poses, meditation, breathing exercises and group discussions. The second group of women — the control group — received standard medication treatments for fibromyalgia.

Following completion of the yoga program, researchers assessed each study subject using questionnaires and physical tests. The results were then compared with testing results obtained prior to the yoga classes. The members of the control group underwent the same evaluations. In addition, each participant in the yoga group was urged to keep a daily diary to personally assess their condition throughout the entire program.

Comparison of the data for the two groups revealed that yoga appears to assist in combating a number of serious fibromyalgia symptoms, including pain, fatigue, stiffness, poor sleep, depression, poor memory, anxiety and poor balance. All of these improvements were shown to be not only statistically but also clinically significant, meaning the changes were large enough to have a practical impact on daily functioning. For example, pain was reduced in the yoga group by an average of 24 percent, fatigue by 30 percent and depression by 42 percent.

“One likely reason for the apparent success of this study therapy was the strong commitment shown by the study subjects. Attendance at the classes was good as was most participants’ willingness to practice yoga while at home,” added Carson. “Based on the results of this research, we strongly believe that further study of this potential therapy is warranted.”

As an outcome of this study and Carson’s previous research showing yoga can be helpful with cancer-related pain, next June the OHSU Department of Anesthesiology and Perioperative Medicine will be sponsoring a training course for U.S. and Canadian yoga teachers who want to build their skills for working with individuals who have chronic pain.

Literature:

Oregon Health & Science University, OHSU research suggests yoga can counteract fibromyalgia, 14-Oct.-2010

Futher Environmental Medicine Matters Articles about Fibromyalgia:

• Quality management is required in the diagnosis of fibromyalgia and MCS
• Unanimous Vote for Research Center for MCS, CFS, FMS, GWS in New Jersey
• New Criteria Proposed for Diagnosing Fibromyalgia
• Fibromyalgia Patients Show Decreases In Gray Matter Intensity

Daily chemical exposures at low doses can affect our health

ROME – On September 24, 2010, from 8:30 a.m. to 5:30 p.m., the congress “New Environmental Diseases” was held at the Chamber of Deputees Congress Hall in Rome. The event was organized by A.M.I.C.A. (Association for Environmental and Chronic Toxic Injury), the Italian organization that works for the rights of people with MCS and EHS, and it was supported by Mep Domenico Scilipoti, an oncologist, holistic doctor, and rapporteur of a draft to become law on environmental diseases and disabilities and also for the phasing out of dental amalgam.

“More and more scientific evidence shows how daily chemical exposures at low doses can affect our health. With this event we would like to create a bridge between science and politics in order to have a new legislation, particularly for the protection of those affected by Multiple Chemical Sensitivity, Electromagnetic Hyper Sensitivity, Chronic Fatigue Syndrome and Fibromyalgia. These diseases seem to be correlated one to another,” Francesca Romana Orlando, Vice President of A.M.I.C.A., commented. She has just published the book Il Cerchio Perfetto (The Perfect Circle) about the link between industry, politics, academics, and media and its role in the hiding of toxic dangers to the public.

“Just a few weeks ago, at the Senate Commission for Health, the debate about the draft to become law for the recognition of MCS as an epidemic disease started. The prevalence of this illness is about 10% of the population and in Italy the patients still don’t have any hospital to receive any medical treatment in a proper environment,” Silvia Bigeschi, Vice President of A.M.I.C.A., adds.

There are ten projects to become law for the recognition of MCS as an epidemic disease at the Italian Parliament and, just the day before of the congress, A.M.I.C.A. presented a petition with more than 10,000 signature asking for the approval of a law for MCS and also a petition to the Ministry of Health for the total phase out of dental mercury (amalgam), since many cases of MCS, CFS and EHS seem to be triggered by amalgam fillings.

The congress was divided in four sessions. The first one was about “Diagnostic approaches” for MCS, CFS and FM. Prof. Giuseppe Genovesi of the University of Rome La Sapienza and Dr. Chiara De Luca, Head of the Laboratory BILARA at the Dermatological Institute Immacolata of Rome, presented the results of a study on oxidative stress and genetics in MCS patients, that was recently published on Toxicology Applied Pharmacology (Apr. 26, 2010).

While Dr. De Luca focused on the clear evidence of oxidative stress in these patients, such as the lack of enzyme catalysis and GST, Prof. Genovesi stressed the fact that the results don’t show the prevalence of one specific genetic polymorphism, but most of the patients had one or more genetic factors inducing a lower detoxification. He also announced that they are going to test the genetic predisposition of the enzyme catalysis, since this is so typically low in MCS patients.

Dr. Alberto Migliore, the chief of Rheumatology Department at the S. Pietro Fatebenefratelli Hospital in Rome, published a study about the comorbidity of MCS and Sjogren Syndrome. Dr. Lorenzo Bettoni presented a lecture about the environmental causes of CFS and FM, with an hypothesis about the role of chemicals, EMF pollution, and physical/mental stress on the triggering of these illnesses.

Dr. Giacomo Rao, who works for the Italian National Insurance of Workers (INAIL, the public institute that gives compensation and pension to the workers injured at workplace), talked about the legal aspects of the recognition of these illnesses as a disability. He showed that there are several impact life factors to consider and that in Italy there are now many MCS disability certificates, even if it is always very difficult to convince the commissions about the severity of this illness. He added that the final judgment depends only on the good will of the commissioners to study a new issue.

In the second session entitled “New Paradigms of Toxicology and Environmental Medicine,” Martin L. Pall, Professor Emeritus of Biochemistry and Basic Medical Sciences, Washington State University, presented his theory about the biochemical vicious cycle ON/ONOO – induced by the combination of high NOS activity and Tetrahydrobiopterin (BH4) depletion – and how it is able to explain not only MCS, CFS or FM, but also other emerging neuro-degenerative illnesses such AD, Parkinson or ALS. He commented that the De Luca – Genovesi study about oxidative stress represents a full confirmation of his theory.

Dr. Peter Ohnsorge, President of the European Academy for Environmental Medicine (EUROPAEM), has already applied Pall’s theory to his clinical approach in order to reduce NMDA in the cerebral metabolism. He proceeds in treating inflammation first, by supplementing enzymes, antioxidants, minerals and Vitamins. Then, he offers a chelation therapy, when possible, and also hemapheresis (Membrane Differential Filtration), gut therapy and detoxification. He also uses sauna therapy since the heat helps to increase BH4 and to oppose the vicious NO/ONOO cycle.

Recently, Dr. Ohnsorge was commissioned by the German Ministry of Health and Social Affairs, to do a controlled randomized study about the efficacy of therapies for MCS patients with the double aim of detoxification of lipophilic toxins and improving the complaints. He found out that using a complex therapeutic regime usually allows the patients to recover slowly, but surely.

The MCS people in the audience asked him several questions, for example about the bad secondary effects of supplementation of glutathione (GSH) and about the tests of compatibility of drugs and dental materials. He explained that supplementation has to be given always with very low doses at the beginning in order to avoid violent breaks in the detoxification mechanisms. Moreover, he suggested using the Lymphocyte Transformation Test (LTT) to find out reactions to drugs, metals, plastics and environmental toxins, while the basophil degranulation test is suggested when inflammation is suspected induced by metals, like in the case of titanium implants.

In the same second session, Dr. Ernesto Burgio, Coordinator of the Scientific Committee of ISDE Italia (Doctors for the Environment), gave a lecture about the epigenetic damages caused by environmental toxins and EMFs. The epigenome represents the interface between the information from the environment and the genome, and even in the absence of chromosomal or gene mutations, there still can be a change in the expression of the gene (DNA Methylation) because of an epigenetic injury. “With a few exceptions, cellular differentiation almost never involves a change in the DNA sequence itself,” commented Dr. Burgio.

Since the environment changed too quickly in the latest decades, the capacity of adaptation of the (epi) genome is not enough to compensate it. Thus, a toxic exposure from the parents, in the womb, or during the early childhood can induce a chronic disabling illness later in life.

New studies are being explored on how a lead exposure in infants can be associated to Alzheimer’s disease (AD)-like symptoms years later or how the mother’s exposure to high levels of folic acid, vitamin B12 or to cigarette smoke can induce epigenetic changes that can repress gene transcription and, then, induce phenotypes of asthma (i.e. allergic airway inflammation) in the offspring. These findings could lead to the conclusion that our society is on the edge of a “disevolution.”

In the third section on “Heavy Metals Toxicity,” Dr. Raimondo Pische, President of the International Academy of Bio-Dentistry (AIOB) talked about the risks associated with the exposure to the metals of dental amalgam. In particular, he presented a video of an amalgam fillings showing how mercury vapors are easily released by the amalgam. He underlined the fact that the dentists are the first ones at risk when they pose and remove amalgam fillings and that dental mercury represents the main source of exposure to mercury vapors in not occupational environments. This is no longer acceptable since mercury is the most toxic element in nature after the radioactive elements.

Dr. Antonello Maria Pasciuto, Italian member of the European Academy for Environmental Medicine (EUROPAEM), talked about the LTT-MELISA, the Lymphocyte Transformation Test for the proof of late allergy to metals (type IV). This kind of allergy was observed in patients with MCS, CFS, MS, FM, ALS and autoimmune diseases and it usually improves, as well as the symptoms, after the safe removal of dental metals.

Dr. Gianpaolo Guzzi of the Italian Organization for the Research on Metals and Biocompatibility (A.I.R.M.E.B.) talked about the side effects of chelation therapies. His group studied hundreds of patients with amalgam toxic load and they reviewed the effects of EDTA, DMPS, DMSA and Glutathione. EDTA seems to redistribute metals without really getting rid of them, while DMPS seems more effective on treating elemental mercury, but with severe side effects in some cases. DMSA works to detoxify from methyl mercury and it can also get rid of elemental mercury stocked in the kidneys. Recently Dr. Guzzi’s research group is testing the efficacy of Glutathione in metal detoxification since there aren’t studies about it.

In the last session about “EMF and Health”, Dr. Fiorenzo Marinelli, researcher of the Institute of Molecular Genetics (IGM) in Bologna talked about wireless technologies such as mobile phones, Wi-Fi and Wi-Max. He pointed out the fact that thermal effects are only a part of the biological effects of EMFs, but still these are the only ones considered by international safety standard limits. There are also other effects induced by the signal information in itself. This explains why, even though UMTS has usually a lower intensity of the signal compared to GSM, it uses a wider band of frequencies, then involving a greater risk of damage in the DNA, as the recent European Reflex study showed. His research group has recently studied the effects of radars and Wi-Fi and the preliminary findings show that both these kind of EMFs promote cell proliferation (2010).

Since scientific literature clearly demonstrates that EMF in our everyday life can induce DNA breakage, genetic deregulation as well as chromosomal breakage, increase of free radicals, alteration of neurotransmitters, memory loss, hypersensitivity-allergy, aging and possibly cancer, Dr. Marinelli supports the reduction of the safety limit of exposure to 0,6 V/m, as requested by the International Commission for the Electromagnetic Safety (ICEMS) since 2002.

Finally, Prof. Olle Johansson, associate professor at The Experimental Dermatology Unit – Department of Neuroscience of the Karolinska Institute, and Professor at The Royal Institute of Technology, Sweden, also member of the famous Bioinitiative Working group, presented a lecture about Electro-Hyper-Sensitivity, which is fully recognized as a functional impairment in Sweden. He explained not only the bioeffects of EMF on EHS people, but also the social problem of disability in our modern societies. “Disability is everywhere and it can happen to anyone: I myself have a disability when I am in Italy because I can not speak Italian,” Prof. Johansson commented. He reminded that all modern democracies signed international equal rights UN treaties, but still they leave these principles un-realized when it comes to environmental disability.

Reference:

A.M.I.C.A. congress shows how environmental and chemical pollution cause health injuries and disabilities, Rome, September 25th, 2010

Photo: AMICA

Contact:

Francesca Romana Orlando
Vice President of AMICA
Associazione Malattie da Intossicazione Cronica e/o Ambientale
(Association for Environmental and Chronic Toxic Injury)
P.O. Box 3131, 00121 Rome – Italy
www.infoamica.it amica(at)infoamica.it

Related articles:

• Predictions of Multiple Chemical Sensitivity Mechanism confirmed by Roman Study
• Martin Pall about genetic evidence and Multiple Chemical Sensitivity
• Italian Parties united under the MCS cause
• An Italian law proposal for Environmental Illness and Disability

There is a connection between fibromyalgia and MCS confirmed by studies. Patients suffering with fibromyalgia (FM) have reported frequent complaints which are outside of their problem area of the musculoskeletal system, and chemically sensitive patients, in addition to their reactions to low doses of chemicals, repeatedly experience pain in different body regions. Fibromyalgia is commonly regarded as an atypical soft-tissue rheumatism. The diagnosis is made mainly by an examination of 18 pressure sensitive parts of the body, called tender points. Scientists from Scandinavia reported more than ten years ago that there is an overlap between MCS and fibromyalgia, which has major relevance for the medical diagnosis for patients. A recent Canadian study in February 2010 confirmed this result. The authors of this study, in a medical journal, appealed for adequate education and specific related information in the health field and to the public in order to improve the prognosis for patients.

Pain on pain

Patients with fibromyalgia or chemical sensitivity often experience pain which they describe as a “toothache all over the body.” Scientists from Scandinavia reported in the late nineties of the existing relationship between these two diseases.

What exists for fibromyalgia patients also exists for MCS patients?

The objective of a pilot university rheumatology study was to determine how often MCS occurs in patients with Fibromyalgia. The research team designed a questionnaire decided whether the patients indeed also had MCS. The physicians used criteria from a new study by using an immunological profile of patients who could be identified with this disease. Patients responded with a yes or no response to confirm the presence of 48 FM-related symptoms. (1)

Study finds link between MCS and FMS

The results of the study were published in the first half of 1997 in the medical journal, “Scandinavian Journal of Rheumatology.” Thirty-three of the 60 patients with fibromyalgia fulfilled the criteria for MCS. Eleven of those patients met more restrictive criteria, which demonstrated the high severity of chemical sensitivity. In addition, scientists found that the sensitivity symptoms and reactions of the triggering substances that were most frequently cited by the FM patients were similar to those reported by MCS patients in other studies. A chemical sensitivity existed in more than half the patients with fibromyalgia, thus the Scandinavian researchers concluded that MCS may be an additional symptom in the complex spectrum of fibromyalgia.

Canadian study confirmed the simultaneous existence of MCS and FMS

The fact that both conditions exist simultaneously has been affirmed by studies in recent years. The targeted diagnosis should be considered because of the potentially dramatic effects on the sufferers of MCS and FMS. This was evident in a study of the environmental clinic (EHC) in Toronto. The Canadian researchers studied 128 patients for the presence of MCS, CFS, and FMS, and identified the impacts in their everyday lives. Eight of the 70 patients received the MCS, CFS, or FM diagnosis, while the remaining patients had two or three overlapping diagnoses. What a great impact in the study of environmental disease for patients and readers of the magazine for Canadian GP, in the February 2010 edition. Most of the study participants (68%) had to leave work, on the average of three years after the onset of their symptoms due to their illness. (2)

Relevance for the diagnosis of environmental and mainstream medicine

The studies of 1997 and early 2010 reveal that medical practices must take a thorough medical history of the patient and make an appropriate diagnosis at the onset of one of these two diseases of FM or MCS. After the clinical results indicate a patient has MCS, then there needs to be a clarification whether or not the patient also has fibromyalgia. This can be detected with little effort by any doctor by checking the 18 tender points. At the same time, fibromyalgia patients must be asked about a hypersensitivity to chemicals which is likely, despite the lack of the study results being integrated into mainstream medicine over the last ten years. It is extremely important for rheumatologists to be familiar with the diagnosis of MCS for their FM patients. The prognosis for fibromyalgia patients significant improvement could be then specifically targeted with treatments and appropriate prevention strategies which deal with the triggering affects of chemicals.

Author: Silvia K. Müller, CSN – Chemical Sensitivity Network, August 2010

Translation: Thank you to Christi Howarth.

Related articles:

• New Criteria Proposed for Diagnosing Fibromyalgia
• Unanimous Vote for Research Center for MCS, CFS, FMS, GWS in New Jersey
• Research on Multiple Chemical Sensitivity (MCS)
• Fibromyalgia Patients Show Decreases In Gray Matter Intensity

P.A.N.D.O.R.A. NeuroEndocrineImmune (NEI) Center Resolution Approved by the New Jersey State Senate

Coral Gables, FL, July 17, 2010 –(PR.com)– Resolution SR-20 supporting the establishment of the NeuroEndocrineImmune (NEI) Center™, the first research center in the state of New Jersey and in the U.S., dedicated to understanding and treating chronic neuroendocrineimmune (NEI) illnesses which includes chronic fatigue syndrome, fibromyalgia, multiple chemical sensitivity, Gulf War Illness and other bacterial & viral infections chronic illnesses was passed unanimously by 38-0 votes by the New Jersey State Senate on June 10, 2010.

Senate Resolution (SR) 20, sponsored by Senator Christopher “Kip” Bateman (R), Senate Deputy Conference Leader, and Senator Loretta Weinberg (D), Chair of the Senate Health Committee, cited studies that an estimated 20 million American adults and children suffer with NEIDs. The economic impact and loss of worker productivity in the United States due to CFS/ME, alone, is estimated to be over $9 billion per year. Chronic illness represents 75% of all the health care costs in the U.S.

“It makes sense to locate the NEI center in New Jersey,” said Senator Weinberg. “As the nation’s medicine chest, New Jersey is home to research institutions and private businesses that can cooperate to find a cure for these debilitating diseases.”

Senator Bateman added, “I look forward to the passage of Senate Resolution 20, solidifying legislative support for the research center, and have high hopes that this will, in fact, be a great step forward toward finding answers for the sufferers of these debilitating diseases.”

Assembly Resolution 202 passes unanimously

Late last year, a similar resolution unanimously passed the New Jersey State Assembly 78-0. “Having a research center… is essential to promoting research into the etiology of, and therapeutic interventions for neuroendocrineimmune disorders (NEIDs),” according to Assembly Resolution (AR) 202 which was sponsored by Assemblyman Upendra Chivukula (D), Deputy Speaker; Assemblyman Herb Conaway, Jr. (D), Chairman, Health Committee; Assemblywoman Connie Wagner (D), Vice-Chairman; and Assemblywoman Mary Pat Angelini (R), member of the Health Committee

P.A.N.D.O.R.A. partners with the Lanford Foundation-Lifelyme™, Inc.

To be based in Newark, New Jersey, the NeuroEndocrineImmune (NEI) Center™ is a community patient-driven project of P.A.N.D.O.R.A, (Patient Alliance for Neuroendocrineimmune Disorders Organization for Research & Advocacy, Inc) in partnership with the Lanford Foundation-Lifelyme™, Inc.

The NEI Center™ is the first research center to incorporate scientific and clinical research, quality in patient care, and social services, all in one state-of-the art facility. The establishment of The NEI Center™ is based on the philosophy that the similarities in symptoms of neuroendocrineimmune disorders (NEIDs) are the human body’s response to similarities in the underlying pathophysiologies that cause these disorders.

The cornerstone of the NEI Center’s mission is that discoveries and advances made in any one of the NEIDs will be applicable and beneficial to other NEIDs, thereby bringing medical researchers closer to a cure. At its inception, the NEI Center™ will include research of the following disorders/illnesses:

Chronic fatigue syndrome (CFS), fibromyalgia (FM), Gulf War syndrome or illness (GWS/I), multiple chemical sensitivity (MCS), and other associated bacterial and viral illnesses.

“Moral and political victory,” said Marly Silverman, a CFS and fibromyalgia patient who founded P.A.N.D.O.R.A. in July 1, 2002, “On behalf of P.A.N.D.O.R.A., we are mindful of the historical significance of the unanimous vote by the New Jersey Senate as well as by the New Jersey Assembly in 2009. Patients across this country will be celebrating what is an amazing and pivotal moment in the history of the neuroendocrineimmune disorders community. The New Jersey Legislature has demonstrated a caring commitment to a community of patients who for the first time in the state of New Jersey can look forward to a brighter and fruitful future.”

Veny W. Musum, chairman of the NEI Center Project, who was diagnosed with chronic Lyme disease in 2004 along with his wife, Patricia, added, “The passage of SR 20 is a moral and political victory for millions of individuals stricken with neuroendocrineimmune disorders who have been living far too long without the compassionate support, research and treatment options they deserve. I am proud of my state of New Jersey!”

Advocates Extraordinaire™ & community support

“The overall community support has been outstanding for this patient-driven, physician-approved project. The unanimous votes by each New Jersey senator came about because of the involvement of individuals who participated in the Advocate Extraordinaire™ program, by making calls, writing e-mails and thanking the New Jersey Legislature for their vision and support of the Center,” said Dr. Kenneth Friedman, one of the founding board trustees of the NEI Center, as well as former member of the CFS Advisory Committee, and a member of the Executive Board of P.A.N.D.O.R.A.

“The New Jersey legislators unanimous support for the NEI Center reflects the kind of leadership needed to bring about positive change in our nation’s Health Care,” said Sandi Lanford, Co-founder of the NEI Center™ and the President-Founder of the Lanford Foundation-Lifelyme™, Inc, who was born and raised in New Jersey. The overall community support has been outstanding for this patient-driven, physician- approved project. The unanimous votes by the New Jersey Legislature came about because of the involvement of individuals who participated in the Advocate Extraordinaire™ program, by making calls, writing e-mails and thanking the New Jersey legislators for their vision and support of the Center,” said Dr. Kenneth Friedman, one of the founding board trustees of the NEI Center, as well as former member of the CFS Advisory Committee, and a member of the Executive Board of P.A.N.D.O.R.A.

Dr. Lesley Fein, member of the NEI Center Project team, stated “This center will be a beacon of hope for patients nationwide, and a place which will bring scientific innovation in New Jersey as well as in the rest of the country.”

Present at the passage of the law were Veny Musum, Chairman of the NEI Center Project and Debbie Floyd, team member of the NEI Center™ project.

NEI Center set to open by 2012

The NEI Center founders are already preparing fundraising efforts to make the Center operational by late 2011-early 2012. For more information about The NEI Center™, visit www.neicenter.com.

-

About P.A.N.D.O.R.A., Inc- Patient Alliance for Neuroendocrineimmune Disorders Organization for Research & Advocacy – Based in Coral Gables, Florida, P.A.N.D.O.R.A. was founded on July 1, 2002 by Marly C. Silverman, a chronic fatigue syndrome and fibromyalgia patient. Its mission is to raise awareness of the plight of persons with chronic fatigue syndrome, fibromyalgia, chronic Lyme disease, multiple chemical sensitivities/EI, and Gulf War illness, and advocate on quality of life issues. P.A.N.D.O.R.A.is Built on Hope – Strong on Advocacy – Finding a Cure through Research. For more information, visit www.pandoranet.info.

Dr. Martin Pall’s theory about MCS confirmed

FOR IMMEDIATE RELEASE

Portland, OR – July 5, 2010 – The physiological mechanism for Multiple Chemical Sensitivity proposed by biochemist Martin L. Pall has been confirmed with the recent findings of an independent research group in Rome.

Multiple chemical sensitivity (MCS), also known as chemical sensitivity and toxicant-induced loss of tolerance (TILT), is a disease initiated by toxic chemical exposure, leading to toxic brain injury that produces high level sensitivity to the same set of chemicals that are implicated in initiation of the disease. Sensitivity responses in other areas of the body are also often seen.

“Epidemiological studies show that MCS is a stunningly common disease, even more common than diabetes,” said Pall, professor emeritus of biochemistry and basic medical sciences at Washington State University. “My review of the literature and other research I’ve conducted over the past eleven years shows the probable central mechanism of MCS is a biochemical vicious mechanism, known as the NO/ONOO- cycle.”

Pall’s work is widely published in books and articles, the most recent of which is a chapter in the authoritative international reference manual for professional toxicologists, General and Applied Toxicology, 3rd Edition, 2009.

The NO/ONOO- cycle

The NO/ONOO- cycle, pronounced no-oh-no, is named for the chemical structures of nitric oxide (NO) and peroxynitrite (ONOO-). This biochemical vicious cycle mechanism predicts that each of the elements linked together in the cycle are elevated in patients suffering from MCS and related diseases. Most of the elements of the cycle have been shown to be elevated in such related diseases as chronic fatigue syndrome and fibromyalgia and also in animal models of MCS. However, several cycle elements have never been measured in MCS patients.

The recent study conducted by the research group in Rome is significant in regard to the NO/ONOO- cycle theory because it shows that three elements of the cycle are elevated in MCS patients (De Luca et al, Toxicology and Applied Pharmacology, 2010, April 27 Epub ahead of print). Those elements are the inflammatory cytokines, nitric oxide, and oxidative stress. Each of these measurements provides important confirmation of the disease mechanism proposed by Pall.

The inflammatory cytokines and nitric oxide elevation have never before been measured in MCS patients, although they have been shown to be elevated in animal models of MCS. Oxidative stress has been reported in two earlier studies of MCS patients, but the data provided in the De Luca et al study are much more extensive than are the earlier data. Consequently, these new data all provide important confirmation of the NO/ONOO- cycle as the central disease mechanism in MCS.

The NO/ONOO- cycle also is useful in understanding the role of toxic chemicals in MCS and the role of treatment. Each of the seven classes of chemicals implicated in MCS are thought to act indirectly to increase the activity of the NMDA receptors, which are glutamate receptors for controlling synaptic plasticity and memory function. This activity, in turn, leads to rapid increases in intracellular calcium (Ca2+), nitric oxide and peroxynitrite (ONOO-), acting to greatly stimulate the NO/ONOO- cycle.

“Many of the agents used by environmental medicine physicians to treat MCS patients can be viewed as lowering different parts of the cycle, and thus are validated in part by this mechanism,” Pall said. “Consequently, the NO/ONOO- cycle mechanism can be viewed as validating therapeutic approaches used in environmental medicine in the U.S., in Germany and some other areas of Europe and in some other countries.”

Contact:

Martin L. Pall, PhD

Professor Emeritus of Biochemistry and Basic Medical Sciences

Washington State University

(1*) 503-232-3883

martin_pall@wsu.edu

Main web site: www.thetenthparadigm.org

German Website: www.martinpall.info

Related Articles:

• MCS – Multiple Chemical Sensitivity, a disease caused by toxic chemical exposure
• Martin Pall about genetic evidence and Multiple Chemical Sensitivity
• Chemical Sensitivity – MCS and a number of medical conditons respond positively to Sauna Therapy
• MCS-Multiple Chemical Sensitivity at “General and applied Toxicology 3rd Edition”